New York Medicaid and SPRAVATO®
What to know about eligibility, prior authorization, billing, and treatment in Manhattan or Melville.
Request a consultationYes, New York Medicaid has published criteria for SPRAVATO® (esketamine), but coverage is not automatic. For treatment-resistant depression, the state lists prior authorization, a baseline depression assessment, and a trial of at least two oral antidepressants. Continued treatment calls for assessment of improvement every six months.
Your plan, provider, treatment setting, and billing pathway must be checked before care. Review New York Medicaid’s SPRAVATO criteria.
New York State Medicaid lists clinical criteria for esketamine nasal spray. Eligibility depends on the indication and applicable pharmacy or medical benefit rules. SPRAVATO is an FDA-approved nasal spray for adults with treatment-resistant depression, as monotherapy or with an oral antidepressant. It is also approved, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. See the FDA prescribing information.
Coverage for SPRAVATO does not establish coverage for IV ketamine. Each treatment has a separate clinical and insurance status.
| Coverage question | What the published policy says |
|---|---|
| Prior authorization | Required under applicable New York Medicaid criteria. |
| Baseline assessment | Prescriber attests to a validated baseline depression score. |
| TRD treatment history | Trial of at least two oral antidepressants before SPRAVATO for TRD. |
| Continued treatment | Every six months, prescriber attests to improvement using the same assessment tool. |
| Billing | Medication and observation may have separate billing pathways. |
Sources: NYS Medicaid practitioner-administered policy and August 2022 Medicaid guidance.
For treatment-resistant depression (TRD), New York Medicaid requires a trial of at least two oral antidepressants and a baseline score from a validated depression tool, such as HAMD-17, QIDS-C16C, or MADRS. Read the state prior-authorization update.
After treatment starts, the prescriber must attest every six months that symptoms improved from baseline using the same tool. This supports continuation review. See New York Medicaid policy guidance.
Yes. The treatment team may need to submit evidence that the applicable clinical criteria are met. New York provides a SPRAVATO clinical criteria worksheet for documentation.
The medication, administration, observation, and other clinical services can be processed differently. New York Medicaid’s pharmacy and medical billing guidance describes drug procurement and separate observation and monitoring pathways. Confirm how your own plan and treatment site handle each component.
| Visit component | Ask your plan or clinic |
|---|---|
| SPRAVATO medication | Is the drug authorized, and through which benefit? |
| Administration | Is treatment covered at this site? |
| Observation and monitoring | How is post-dose monitoring billed? |
| Provider services | Does the provider participate with my coverage? |
| Evaluation and follow-up | Are separate visits covered? |
SPRAVATO is supplied through the restricted FDA REMS program. Patients self-administer it under healthcare supervision and are monitored for at least two hours afterward because of risks including sedation, dissociation, and respiratory depression. FDA prescribing information.
New York Ketamine Infusions offers SPRAVATO treatment in Manhattan. Before scheduling, verify your individual Medicaid benefits, authorization, antidepressant history, depression assessment, and billing for the full visit.
New York Ketamine Infusions also offers SPRAVATO treatment in Melville. Statewide clinical rules may apply, while plan participation, authorization, and billing still require individual verification.
Review the stated denial reason with your treatment team and Medicaid plan. Missing documentation, treatment history, authorization requirements, network status, or billing pathways may be involved. Ask whether additional documentation, reconsideration, or an appeal applies to your case.
No automatic overlap exists. New York Medicaid’s criteria on this page address esketamine nasal spray. SPRAVATO and IV ketamine differ in formulation, FDA status, delivery, and coverage decisions. Check the benefit for each separately.
Give your plan your member details, the proposed treatment site, and the name esketamine nasal spray (SPRAVATO). Ask which benefit processes the medication, whether prior authorization is approved, whether the clinic participates, and how administration and observation are billed. New York describes several possible billing paths in its SPRAVATO guidance.
Potentially. New York moved most Medicaid pharmacy benefits to NYRx, while some managed care arrangements may handle the drug with observation as a bundled benefit. Ask your plan and treatment team which pathway applies to you and confirm approval before starting. See the NYRx transition FAQ.
Check the provider directory for your specific plan and call the clinic with your plan name and member information. Confirm the treating provider and location, not only whether the drug appears in a formulary. A listing or benefits check does not guarantee authorization or payment.
No home pickup for self-treatment: SPRAVATO is supplied and administered through a certified healthcare setting. The drug may be supplied through a REMS-certified specialty pharmacy or procured by the provider, depending on the approved billing route. See New York billing guidance and the FDA label.
There is no single reliable amount for every member. Ask your plan and treatment site about any applicable copayment and the medication, administration, evaluation, and monitoring charges. New York’s NYRx coverage page explains that pharmacy copayments can vary by drug category.
Request the denial reason from your plan. Your prescriber can review whether the diagnosis, two prior oral antidepressant trials for TRD, baseline score, or other documents need correction. Ask the plan which reconsideration or appeal process applies to your decision.
Clinical suitability is separate from insurance approval. The FDA label lists contraindications, including certain aneurysmal vascular diseases, arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine or ketamine. A clinician must assess your history, blood pressure, current medications, and other risks individually.
Tell the prescriber about all prescription drugs, over-the-counter products, and substances you use. The FDA prescribing information calls for attention to central nervous system depressants and to blood pressure with psychostimulants or monoamine oxidase inhibitors. Do not stop prescribed medication without medical advice.
New York Medicaid publishes coverage and authorization criteria. Approval depends on your clinical history and applicable plan and billing requirements.
The published New York Medicaid criteria require a trial of at least two oral antidepressants before SPRAVATO for treatment-resistant depression.
Yes, the published New York Medicaid SPRAVATO criteria include prior authorization.
New York Medicaid publishes observation and monitoring billing guidance. Verify how your plan handles those services at your treatment site.
No. SPRAVATO is administered in a REMS-certified healthcare setting with post-dose observation.
No. SPRAVATO is esketamine nasal spray. IV ketamine is a different treatment with separate insurance considerations.
Yes. New York Ketamine Infusions offers SPRAVATO treatment in Manhattan. Verify coverage and clinical eligibility before treatment.
Yes. New York Ketamine Infusions offers SPRAVATO treatment in Melville, Long Island. Verify coverage and clinical eligibility before treatment.
Our Manhattan and Melville teams can discuss clinical eligibility and the next steps for checking your insurance benefits.
Request a consultationInsurance note: Medicaid policies, formularies, billing rules, and individual eligibility may change. Benefits verification or authorization does not guarantee payment. Confirm current coverage with your plan and treatment provider.
